Cargando…
PROTACs: A novel strategy for cancer drug discovery and development
Proteolysis targeting chimera (PROTAC) technology has become a powerful strategy in drug discovery, especially for undruggable targets/proteins. A typical PROTAC degrader consists of three components: a small molecule that binds to a target protein, an E3 ligase ligand (consisting of an E3 ligase an...
Autores principales: | Han, Xin, Sun, Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10227178/ https://www.ncbi.nlm.nih.gov/pubmed/37261210 http://dx.doi.org/10.1002/mco2.290 |
Ejemplares similares
-
Editorial: Application of PROTACs as a Novel Strategy for Drug Discovery
por: Ibrahim, Hany S., et al.
Publicado: (2021) -
An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022) -
The PROTAC technology in drug development
por: Zou, Yutian, et al.
Publicado: (2019) -
PROTAC: targeted drug strategy. Principles and limitations
por: Koroleva, O. A., et al.
Publicado: (2022) -
Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)